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Good data collection is essential for a better understanding 
of Buruli ulcer 
Buruli ulcer is a necrotising skin and soft tissue disease 
caused by the environmental bacterium Mycobacterium 
ulcerans. The organism belongs to the same family as 
those that cause leprosy and tuberculosis, but uniquely, 
M ulcerans produces the toxin mycolactone, which 
causes tissue damage. Clinical manifestations include 
nodules, oedema, and plaques, but the most typical 
presentation is a large ulcer, usually on the limbs. Buruli 
ulcer is rarely fatal, but victims are often left deformed 
and with permanent disability. 
Under-reporting of the disease is a major problem 
in several countries. Although advances in treatment 
have been made with WHO’s recommendation1 of the 
use of combined antibiotic treatment with rifampicin 
and streptomycin for 8 weeks for all types of lesion, 
laboratory conﬁ rmation of clinical diagnosis is still a 
limiting factor. The development of a PCR test that 
targets IS2404 (an insertion sequence found on the 
M ulcerans genome) allows accurate diagnosis, but is 
available only in reference laboratories that are far from 
areas endemic for Buruli ulcer.2 Microscopy is available 
in local health facilities, but is less sensitive than PCR 
testing. To ensure standardised recording and reporting 
of cases, WHO developed the Buruli ulcer clinical and 
treatment 01 form3 to collect clinical and laboratory data 
for all patients with suspected or conﬁ rmed Buruli ulcer. 
The study by Quentin Vincent and colleagues4 in 
The Lancet Global Health makes good use of data 
collected with the WHO Buruli ulcer forms. Vincent 
and colleagues exploited and analysed data for 
1357 laboratory-conﬁ rmed cases of Buruli ulcer during 
10 years at the treatment centre in Pobè, Benin, to 
provide qualitative and quantitative information about 
clinical features, diagnosis, treatment, and follow-
up. Unlike other published studies that have included 
clinically diagnosed cases only, this analysis was done on 
laboratory-conﬁ rmed cases of Buruli ulcer, which lends 
signiﬁ cance to the study. In this study, oedema was 
most frequent in children, and in the most severe form, 
led to sequelae in 30% of cases. Plaques and nodules 
were also more frequent in children and all these clinical 
presentations decreased signiﬁ cantly with age. Another 
interesting ﬁ nding is that osteomyelitis caused by 
M ulcerans presented without any skin lesion in 20% of 
cases. Clinicians should therefore pay more attention 
to the diagnosis of osteomyelitis in young people in 
endemic areas. They also need to be aware of the special 
challenges in the diagnosis and management of Buruli 
ulcer according to lesion type.
Some characteristics of the disease reported in other 
studies were also conﬁ rmed by Vincent and colleagues: 
patients with Buruli ulcer were young, with a median age 
of 12 years, lesions were mainly localised in the limbs, 
and 90% of lesions were unifocal. The disseminated non-
ulcerative form of M ulcerans infection as oedema is well 
known and has been reported in severe forms in children.
This study highlights the importance of using the WHO 
form to ensure standard collection of patient data within 
and across endemic countries. National programmes 
should encourage health workers to correctly ﬁ ll out the 
forms and encourage supervisory activities to ensure 
their completeness and accuracy. This prospective 
series of patients is an excellent example of what can 
be achieved when health workers are encouraged to 
correctly ﬁ ll out the forms. The information collected 
can complement other epidemiological information 
about patients’ habits,  location of housing, activities, 
and other health data related to the environment. 
The analyses of these data could further enhance 
understanding of risk factors and help to better develop 
research hypothesis on the transmission. 
A key question that needs to be addressed is why 
children are more vulnerable to the development of 
non-ulcerative forms of Buruli ulcer disease such as 
oedema and osteomyelitis. A point-of-care test that is 
eﬀ ective, eﬃ  cient, and easy to implement on the ﬁ eld is 
urgently needed. Such a test is also essential to exclude 
other common lesions that could mimic Buruli ulcer and 
cause false-positive clinical diagnosis. A less invasive 
sampling method for the oedema and osteomyelitis 
forms of Buruli ulcer is also needed. Converse and 
colleagues5 reported a successful innovation to detect 
mycolactone in tissue; future development of this 
technique could be used as a diagnostic test. 
Despite substantial knowledge about its clinical 
manifestations in some endemic countries, con-
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ﬁ rmation of Buruli ulcer diagnosis is necessary for 
correct management and reporting of cases. Therefore, 
health staﬀ  should be trained to ﬁ ll out the WHO form, 
and physicians should be educated about Buruli ulcer. 
Early diagnosis and treatment, including measures to 
prevent disability, are essential for a good outcome.
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